AIM-100 |
| Catalog No.GC16228 |
An ACK1/TNK2 inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 873305-35-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AIM-100 is a small inhibitor of Ack1 tyrosine kinase with IC50 value of 24 nM [1].
AIM-100 mimicked ATP and inhibited the activity of Ack1 significantly and specifically. It showed no inhibition activity for the other 30 kinases including PI3-kinase and AKT, and showed a five-fold higher IC50 value for Lck. In MEF cells treated with EGF, AIM-100 caused a remarkable decrease of the activation of Ack1. In the human prostate cancer cells LNCaP and LAPC4, AIM-100 treatment resulted in an increase of G0/G1 cell phase and subsequent cell growth suppression. These effects of AIM-100 also exerted in the pancreatic cancer cells. AIM-100 induced apoptosis in Panc-1 cells at concentration of 10 μM. Moreover, AIM-100 inhibited cell growth with GI50 values of 7 to 8 μM in CD-18, Panc-1, OV90, MCF-7 and MDA-MB-468 cancer cells [1, 2].
References:
1. Mahajan K, Challa S, Coppola D, et al. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. The Prostate, 2010, 70(12): 1274-1285.
2. Mahajan K, Coppola D, Chen Y, et al. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. The American journal of pathology, 2012, 180(4): 1386-1393.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *